Syndax Pharmaceuticals Inc (NASDAQ:SNDX) has been given an average recommendation of “Buy” by the eleven research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $26.43.
A number of research firms recently issued reports on SNDX. Zacks Investment Research upgraded Syndax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Wednesday, January 10th. BidaskClub upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 23rd. Finally, B. Riley began coverage on Syndax Pharmaceuticals in a research note on Friday, January 5th. They set a “buy” rating and a $40.00 price objective on the stock.
A number of institutional investors have recently bought and sold shares of SNDX. New York State Common Retirement Fund grew its position in Syndax Pharmaceuticals by 421.9% during the second quarter. New York State Common Retirement Fund now owns 9,400 shares of the company’s stock worth $131,000 after buying an additional 7,599 shares in the last quarter. Trexquant Investment LP purchased a new position in Syndax Pharmaceuticals during the third quarter worth about $133,000. Dynamic Technology Lab Private Ltd purchased a new position in Syndax Pharmaceuticals during the third quarter worth about $154,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Syndax Pharmaceuticals during the third quarter worth about $163,000. Finally, Dimensional Fund Advisors LP purchased a new position in Syndax Pharmaceuticals during the second quarter worth about $192,000. Institutional investors and hedge funds own 59.91% of the company’s stock.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.